Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.

"Declarations Ethics approval and consent to participateNot applicable. Competing interestsA. O: Consultant fee from NMS. Former consultant of Servier, WWIT and CancerAppy. Former employee of Symphogen. V. M: reports personal fees from Bristol-Myers Squibb, Bayer, Janssen, and Pieris outside the submitted work. P. P: Consultant for: Bristol-Myers Squibb, Merck, MSD. Speaker’s Bureau for Bristol-Myers Squibb, Merck, MSD. Employee of: None. Grant/Research support from (Clinical Trials): Bristol-Myers Squibb, AstraZeneca, MSD. Travel Academic work Fees from: Merck, MSD and Bristol-Myers Squibb. E. C. reports grants and personal fees from Astellas, Novartis, Nanobiotix, Pfizer, Janssen-Cilag, PsiOxus Therapeutics, Merck, Bristol-Myers Squibb, Seattle Genetics, Boehringer Ingelheim, AstraZeneca, Roche/Genentech, Servier, Celgene, AbbVie, Amcure, Alkermes, PharmaMar, and BeiGene, personal fees from GLG, Medscape, Gilead, Pierre Fabre, Cerulean Pharma, EUSA, Gehrmann Consulting, Guidepoint, and OncoDNA, and grants from ACEO, Adaptimmune, AMGEN, CytomX, GlaxoSmithKline, H3,Incyte, Kura, Lilly, Nektar, Loxo, MacroGenics, Menarini, Merus, Principia, PUMA, Sanofi, Taiho, Tesaro, Transgene, Takeda, Inovio, MSD, Mersana Therapeutics, Daiichi Sankyo, ORCA, Boston Therapeutics, Dynavax Technologies, Debiopharm, Regeneron, Millennium, Synthon, Spectrum, and Rigontec outside the submitted work. F. M: Former employee of Entrechem. Employee of CancerAppy. No competing interests to declare in relation to this work. Competing interests A. O: Consultant fee from NMS. Former consultant of Servier, WWIT and CancerAppy. Former employee of Symphogen. V. M: reports personal fees from Bristol-Myers Squibb, Bayer, Janssen, and Pieris outside the submitted work. P. P: Consultant for: Bristol-Myers Squibb, Merck, MSD. Speaker’s Bureau for Bristol-Myers Squibb, Merck, MSD. Employee of: None. Grant/Research support from (Clinical Trials): Bristol-Myers Squibb, AstraZeneca, MSD. Travel Academic work Fees from: Merck, MSD and Bristol-Myers Squibb. E. C. reports grants and personal fees from Astellas, Novartis, Nanobiotix, Pfizer, Janssen-Cilag, PsiOxus Therapeutics, Merck, Bristol-Myers Squibb, Seattle Genetics, Boehringer Ingelheim, AstraZeneca, Roche/Genentech, Servier, Celgene, AbbVie, Amcure, Alkermes, PharmaMar, and BeiGene, personal fees from GLG, Medscape, Gilead, Pierre Fabre, Cerulean Pharma, EUSA, Gehrmann Consulting, Guidepoint, and OncoDNA, and grants from ACEO, Adaptimmune, AMGEN, CytomX, GlaxoSmithKline, H3,Incyte, Kura, Lilly, Nektar, Loxo, MacroGenics, Menarini, Merus, Principia, PUMA, Sanofi, Taiho, Tesaro, Transgene, Takeda, Inovio, MSD, Mersana Therapeutics, Daiichi Sankyo, ORCA, Boston Therapeutics, Dynavax Technologies, Debiopharm, Regeneron, Millennium, Synthon, Spectrum, and Rigontec outside the submitted work. F. M: Former employee of Entrechem. Employee of CancerAppy. No competing interests to declare in relation to this work."

"Funding These results have been supported by Instituto de Salud Carlos III (PI19/00808), ACEPAIN, Diputación de Albacete, CIBERONC and CRIS Cancer Foundation (to A.O.)."